Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GenSight Biologics S.A.    SIGHT   FR0013183985

GENSIGHT BIOLOGICS S.A.

(SIGHT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
7.5(c) 8.62(c) 8.33(c) 8.34(c) 8.25(c) Last
480 513 1 445 890 651 743 286 543 333 181 Volume
+1.63% +14.93% -3.36% +0.12% -1.08% Change
More quotes
Financials
Sales 2020 11,5 M 13,8 M 13,8 M
Net income 2020 -19,6 M -23,7 M -23,7 M
Net cash position 2020 6,05 M 7,31 M 7,31 M
P/E ratio 2020 -14,5x
Yield 2020 -
Sales 2021 15,0 M 18,1 M 18,1 M
Net income 2021 -14,1 M -17,0 M -17,0 M
Net Debt 2021 12,4 M 15,0 M 15,0 M
P/E ratio 2021 -23,1x
Yield 2021 -
Capitalization 352 M 426 M 425 M
EV / Sales 2020 30,2x
EV / Sales 2021 24,4x
Nbr of Employees 25
Free-Float 95,4%
More Financials
Company
GenSight Biologics S.A. specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives. At the end of 2019, the company had a portfolio of 2 products, including 1 in phase III clinical development (GS010 for the treatment of Leber's hereditary optic neuropathy) and 1 in phase I/II clinical development (GS030 for the treatment of retinitis... 
More about the company
Notations Surperformance© of GenSight Biologics S.A.
Trading Rating : Investor Rating :
More Ratings
All news about GENSIGHT BIOLOGICS S.A.
01/14GENSIGHT BIOLOGICS S A : - ESSA Pharma Announces Clinical Collaboration with Jan..
AQ
01/13GENSIGHT BIOLOGICS S A : Expects EU Decision on Eye Disorder Drug Lumevoq in Q4
MT
01/13GENSIGHT BIOLOGICS : Announces Publication of Results from LUMEVOQ® RESCUE Pivot..
BU
2020GENSIGHT BIOLOGICS S A : Announces Publication of Results from LUMEVOQ REVERSE P..
AQ
2020GENSIGHT BIOLOGICS : Announces the Partial Conversion of Convertible Bonds and F..
BU
2020GENSIGHT BIOLOGICS : Announces Publication of Results from LUMEVOQ® REVERSE Pivo..
BU
2020GENSIGHT BIOLOGICS S A : reports validation of LUMEVOQ Marketing Authorisation A..
AQ
2020GENSIGHT BIOLOGICS S A : reports validation of LUMEVOQ® Marketing Authorisation ..
PU
2020GENSIGHT BIOLOGICS : Reports Validation of LUMEVOQ® Marketing Authorisation Appl..
BU
2020GENSIGHT BIOLOGICS S A : successfully raises EUR25 million in an oversubscribed ..
AQ
2020GENSIGHT BIOLOGICS S A : Securities Note
PU
2020GENSIGHT BIOLOGICS S A : Amendment to the 2019 Universal Registration Document
PU
2020GENSIGHT BIOLOGICS S A : launches a capital increase of approximately EUR25 mill..
AQ
2020GENSIGHT BIOLOGICS S A : successfully raises €25 million in an oversubscribed pr..
PU
2020GENSIGHT BIOLOGICS S A : Successfully Raises €25 Million in an Oversubscribed Pr..
BU
More news
News in other languages on GENSIGHT BIOLOGICS S.A.
01/13Washington attend la curée
01/13EN DIRECT DES MARCHES : Carrefour, Total, TechnipFMC, Valneva, Esker, Boeing, Vi..
01/13GENSIGHT BIOLOGICS : annonce la publication dans la revue Ophthalmology® des rés..
2020Quand le sage montre la lune, l'idiot regarde le doigt
2020EN DIRECT DES MARCHES : ArcelorMittal, Kering, Sanofi, Solutions 30, Innate, Air..
More news
Chart GENSIGHT BIOLOGICS S.A.
Duration : Period :
GenSight Biologics S.A. Technical Analysis Chart | SIGHT | FR0013183985 | MarketScreener
Technical analysis trends GENSIGHT BIOLOGICS S.A.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 13,00 €
Last Close Price 8,25 €
Spread / Highest target 81,8%
Spread / Average Target 57,6%
Spread / Lowest Target 21,2%
EPS Revisions
Managers and Directors
NameTitle
Bernard Jacques Alex Gilly Chief Executive Officer & Director
Michael S. Wyzga Chairman
Thomas Gidoin Chief Financial Officer
Magali Taiel Chief Medical Officer
José-Alain Sahel Director
Sector and Competitors
1st jan.Capitalization (M$)
GENSIGHT BIOLOGICS S.A.15.71%426
GILEAD SCIENCES, INC.8.70%78 220
VERTEX PHARMACEUTICALS-4.57%58 800
REGENERON PHARMACEUTICALS7.21%54 663
WUXI APPTEC CO., LTD.3.52%53 415
BEIGENE, LTD.33.52%30 634